The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Diabetic retinopathy (DR) is a diabetic complication which affects retinal function and results
in severe loss of vision and relevant retinal diseases. Retinal vascular dysfunction caused …

Background The ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to
decrease certain microvascular events has called for the investigation of GLP-1 RAs against …

Diabetes has become more common in recent years worldwide, and this growth is projected
to continue in the future. The primary concern with diabetes is developing various …

Background Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist
used to treat patients with type 2 diabetes mellitus (T2DM). The SUSTAIN 6 trial found a …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin-mimetic agents that are
effective adjuncts in the treatment of diabetes. This class of medications is also associated …

Background To compare risk of diabetic retinopathy (DR) between patients taking sodium-
glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 …

Aims/hypothesis A protective role of sodium–glucose cotransporter 2 inhibitors (SGLT2is)
and glucagon-like peptide 1 receptor agonists (GLP1-ra) in the development of diabetic …

Diabetic retinopathy (DR) is the leading etiology of blindness in the working population of
the USA. Its long-term management relies on effective glycemic control. Seven anti-diabetic …

Diallyl disulfide (DADS), an oil-soluble sulfur compound that is responsible for the biological
effects of garlic, displays numerous biological activities, among which its anti-cancer …